News

Merck will have 'a lot more work to do' after Verona deal
Merck (MRK) is spending about $10 billion to acquire Verona Pharma (VRNA) as the company looks to fill future revenue gaps.
Merck to Buy Verona for $10 Billion as Patent Cliff Looms
Merck & Co. agreed to buy respiratory drugmaker Verona Pharma Plc for around $10 billion as part of its ongoing search for ...
Barchart on MSN11h
What You Need To Know Ahead of Merck's Earnings Release
Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.
US pharma giant Merck snaps up London lung specialist Verona Pharma for £7.5bn
Merck is looking to strengthen its respiratory treatments as part of efforts to reduce dependence on its blockbuster cancer ...
Fierce Pharma11h
Merck boosts respiratory portfolio with $10B acquisition of Verona and potential COPD blockbuster Ohtuvayre
Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...
Zacks Investment Research on MSN6d
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest ...
Merck & Co.: A Pharma Titan At A Discount
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...